Search Results - "KUSABA, Hitoshi"

Inhibition of insulin‐like growth factor‐1 receptor enhances eribulin‐induced DNA damage in colorectal cancer by Yoshihiro, Tomoyasu, Ariyama, Hiroshi, Yamaguchi, Kyoko, Imajima, Takashi, Yamaga, Satoru, Tsuchihashi, Kenji, Isobe, Taichi, Kusaba, Hitoshi, Akashi, Koichi, Baba, Eishi

“…Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment…”
Get full text

OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody by Ohmura, Hirofumi, Yamaguchi, Kyoko, Hanamura, Fumiyasu, Ito, Mamoru, Makiyama, Akitaka, Uchino, Keita, Shimokawa, Hozumi, Tamura, Shingo, Esaki, Taito, Mitsugi, Kenji, Shibata, Yoshihiro, Oda, Hisanobu, Tsuchihashi, Kenji, Ariyama, Hiroshi, Kusaba, Hitoshi, Oda, Yoshinao, Akashi, Koichi, Baba, Eishi

“…Background Anti-PD-1 monoclonal antibody, nivolumab, has shown efficacy for advanced gastric cancer (AGC). However, the specific immune cell subsets…”
Get full text

Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab by Tanoue, Kenro, Tamura, Shingo, Kusaba, Hitoshi, Shinohara, Yudai, Ito, Mamoru, Tsuchihashi, Kenji, Shirakawa, Tsuyoshi, Otsuka, Taiga, Ohmura, Hirofumi, Isobe, Taichi, Ariyama, Hiroshi, Koreishi, Sakuya, Matsushita, Yuzo, Shimokawa, Hozumi, Tanaka, Risa, Mitsugi, Kenji, Akashi, Koichi, Baba, Eishi

“…Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including…”
Get full text

RHAMM marks proliferative subpopulation of human colorectal cancer stem cells by Nakano, Michitaka, Taguchi, Ryosuke, Kikushige, Yoshikane, Isobe, Taichi, Miyawaki, Kohta, Mizuno, Shinichi, Tsuruta, Nobuhiro, Hanamura, Fumiyasu, Yamaguchi, Kyoko, Yamauchi, Takuji, Ariyama, Hiroshi, Kusaba, Hitoshi, Nakamura, Masafumi, Maeda, Takahiro, Kuo, Calvin J., Baba, Eishi, Akashi, Koichi

“…The cancer stem cell (CSC) theory features typically rare self‐renewing subpopulations that reconstitute the heterogeneous tumor. Identification of molecules…”
Get full text

Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients by Takayoshi, Kotoe, Kusaba, Hitoshi, Aikawa, Tomomi, Koreishi, Sakuya, Sagara, Kosuke, Nakano, Michitaka, Komoda, Masato, Kono, Mihoko, Fukata, Mitsuhiro, Arita, Takeshi, Esaki, Taito, Akashi, Koichi, Baba, Eishi

“…Background Venous thromboembolism (VTE) is highly associated with advanced gastric cancer (AGC) and is sometimes lethal. Predictors of VTE have not been…”
Get full text

Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease by Suzuki, Kunihiro, Yanagihara, Toyoshi, Matsumoto, Koichiro, Kusaba, Hitoshi, Yamauchi, Takuji, Ikematsu, Yuki, Tanaka, Kentaro, Otsubo, Kohei, Inoue, Hiroyuki, Yoneshima, Yasuto, Iwama, Eiji, Arimura-Omori, Masako, Harada, Eiji, Hamada, Naoki, Okamoto, Isamu, Nakanishi, Yoichi

“…Abstract Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes and are becoming a standard treatment for many cancer types. However, these drugs…”
Get full text

Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer by Tanoue, Kenro, Ohmura, Hirofumi, Uehara, Koki, Ito, Mamoru, Yamaguchi, Kyoko, Tsuchihashi, Kenji, Shinohara, Yudai, Lu, Peng, Tamura, Shingo, Shimokawa, Hozumi, Isobe, Taichi, Ariyama, Hiroshi, Shibata, Yoshihiro, Tanaka, Risa, Kusaba, Hitoshi, Esaki, Taito, Mitsugi, Kenji, Kiyozawa, Daisuke, Iwasaki, Takeshi, Yamamoto, Hidetaka, Oda, Yoshinao, Akashi, Koichi, Baba, Eishi

“…Despite the success of immune checkpoint blockade (ICB) therapy for esophageal squamous cell cancer, the key immune cell populations that affect ICB efficacy…”
Get full text

Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy by Moriyama, Shohei, Hieda, Michinari, Kisanuki, Megumi, Kawano, Shotaro, Yokoyama, Taku, Fukata, Mitsuhiro, Kusaba, Hitoshi, Maruyama, Toru, Baba, Eishi, Akashi, Koichi, Fukuda, Haruhisa

“…Background: Hypertension is a frequent adverse event caused by vascular endothelial growth factor signaling pathway (VSP) inhibitors. However, the impact of…”
Get full text

Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer by Yamaguchi, Kyoko, Ito, Mamoru, Ohmura, Hirofumi, Hanamura, Fumiyasu, Nakano, Michitaka, Tsuchihashi, Kenji, Nagai, Shuntaro, Ariyama, Hiroshi, Kusaba, Hitoshi, Yamamoto, Hidetaka, Oda, Yoshinao, Nakamura, Masafumi, Akashi, Koichi, Baba, Eishi

“…Tertiary lymphoid structures (TLSs), clusters of immune cells found around tumor tissue, have been shown to be associated with anti-tumor immunity, but the…”
Get full text

IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism by Kusaba, Hitoshi, Moriyama, Shohei, Hieda, Michinari, Ito, Mamoru, Ohmura, Hirofumi, Isobe, Taichi, Tsuchihashi, Kenji, Fukata, Mitsuhiro, Ariyama, Hiroshi, Baba, Eishi

“…Abstract Background The incidence of venous thromboembolism has been reported as 20% in cancer patients. Anticoagulation therapy is the standard treatment for…”
Get full text

PD‐1+ TIM‐3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer by Nakano, Michitaka, Ito, Mamoru, Tanaka, Risa, Yamaguchi, Kyoko, Ariyama, Hiroshi, Mitsugi, Kenji, Yoshihiro, Tomoyasu, Ohmura, Hirofumi, Tsuruta, Nobuhiro, Hanamura, Fumiyasu, Sagara, Kosuke, Okumura, Yuta, Nio, Kenta, Tsuchihashi, Kenji, Arita, Shuji, Kusaba, Hitoshi, Akashi, Koichi, Baba, Eishi

“…The liquid biopsy of ascites fluid could be an excellent source of tumor and microenvironment for the study of prognostic biomarkers because of its…”
Get full text

Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model by Yamaguchi, Kyoko, Yoshihiro, Tomoyasu, Ariyama, Hiroshi, Ito, Mamoru, Nakano, Michitaka, Semba, Yuichiro, Nogami, Jumpei, Tsuchihashi, Kenji, Yamauchi, Takuji, Ueno, Shohei, Isobe, Taichi, Shindo, Koji, Moriyama, Taiki, Ohuchida, Kenoki, Nakamura, Masafumi, Nagao, Yoshihiro, Ikeda, Tetsuo, Hashizume, Makoto, Konomi, Hiroyuki, Torisu, Takehiro, Kitazono, Takanari, Kanayama, Tomohiro, Tomita, Hiroyuki, Oda, Yoshinao, Kusaba, Hitoshi, Maeda, Takahiro, Akashi, Koichi, Baba, Eishi

“…Background Loss of E-cadherin expression is frequently observed in signet ring carcinoma (SRCC). People with germline mutations in CDH1, which encodes…”
Get full text

Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer by Makiyama, Akitaka, Arimizu, Kohei, Hirano, Gen, Makiyama, Chinatsu, Matsushita, Yuzo, Shirakawa, Tsuyoshi, Ohmura, Hirofumi, Komoda, Masato, Uchino, Keita, Inadomi, Kyoko, Arita, Shuji, Ariyama, Hiroshi, Kusaba, Hitoshi, Shinohara, Yudai, Kuwayama, Miyuki, Kajitani, Tatsuhiro, Oda, Hisanobu, Esaki, Taito, Akashi, Koichi, Baba, Eishi

“…Background Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of…”
Get full text

Activation of central/effector memory T cells and T‐helper 1 polarization in malignant melanoma patients treated with anti‐programmed death‐1 antibody by Yamaguchi, Kyoko, Mishima, Koji, Ohmura, Hirofumi, Hanamura, Fumiyasu, Ito, Mamoru, Nakano, Michitaka, Tsuchihashi, Kenji, Ota, Shun‐Ichiro, Wada, Naoko, Uchi, Hiroshi, Ariyama, Hiroshi, Kusaba, Hitoshi, Niiro, Hiroaki, Akashi, Koichi, Baba, Eishi

“…Human anti‐programmed death‐1 (PD‐1) antibody possesses the capability to revitalize host T cells and has been an effective therapy for metastatic malignant…”
Get full text

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial by Chiba, Yohei, Sudo, Kazuki, Kojima, Yuki, Okuma, Hitomi, Kohsaka, Shinji, Machida, Ryunosuke, Ichimura, Masahiko, Anjo, Kenta, Kurishita, Kazumi, Okita, Natsuko, Nakamura, Kenichi, Kinoshita, Ichiro, Takahashi, Masanobu, Matsubara, Junichi, Kusaba, Hitoshi, Yonemori, Kan, Takahashi, Masamichi

“…Abstract Background Aberrant fibroblast growth factor receptor (FGFR) signaling can substantially influence oncogenicity. Despite that FGFR gene abnormality is…”
Get full text

A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site by Nishikawa, Kazuo, Hironaka, Shuichi, Inagaki, Takashi, Komori, Azusa, Otsu, Satoshi, Mitsugi, Kenji, Makiyama, Akitaka, Watanabe, Koichiro, Tamura, Shingo, Okumura, Yuta, Kusaba, Hitoshi, Esaki, Taito, Baba, Eishi, Shirao, Kuniaki

“…Abstract Background Patients with cancer of unknown primary site are divided into two distinct groups, favourable and unfavourable subsets. For the…”
Get full text

Phase I/II trial of 2‐weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) by Hironaka, Shuichi, Tsubosa, Yasuhiro, Mizusawa, Junki, Kii, Takayuki, Kato, Ken, Tsushima, Takahiro, Chin, Keisho, Tomori, Akihisa, Okuno, Tatsuya, Taniki, Toshikatsu, Ura, Takashi, Matsushita, Hisayuki, Kojima, Takashi, Doki, Yuichiro, Kusaba, Hitoshi, Fujitani, Kazumasa, Taira, Koichi, Seki, Shiko, Nakamura, Tsutomu, Kitagawa, Yuko

“…We carried out a phase I/II trial of adding 2‐weekly docetaxel to cisplatin plus fluorouracil (CF) therapy (2‐weekly DCF regimen) in esophageal cancer patients…”
Get full text

Difference of compliance rates for the recommendations in Japanese Guideline on Febrile Neutropenia according to respondents’ attributes: the second report on a questionnaire survey among hematology-oncology physicians and surgeons by Akiyama, Nobu, Okamura, Takuho, Yoshida, Minoru, Kimura, Shun-ichi, Yano, Shingo, Yoshida, Isao, Kusaba, Hitoshi, Takahashi, Kosuke, Fujita, Hiroyuki, Fukushima, Keitaro, Iwasaki, Hiromichi, Tamura, Kazuo, Saeki, Toshiaki, Takamatsu, Yasushi, Zenda, Sadamoto

“…Purpose The Japanese Society of Medical Oncology (JSMO) published a guideline (GL) on febrile neutropenia (FN) in 2017. This study aims to identify promoting…”
Get full text

E‑cadherin regulates proliferation of colorectal cancer stem cells through NANOG by Tamura, Shingo, Isobe, Taichi, Ariyama, Hiroshi, Nakano, Michitaka, Kikushige, Yoshikane, Takaishi, Shigeo, Kusaba, Hitoshi, Takenaka, Katsuto, Ueki, Takashi, Nakamura, Masafumi, Akashi, Koichi, Baba, Eishi

“…Cancer stem cells (CSCs) possess a self‑renewal ability and display tumorigenic potential in immunodeficient mice. Colorectal CSCs are thought to be a uniform…”
Get full text

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin by Tsuchihashi, Kenji, Kusaba, Hitoshi, Yoshihiro, Tomoyasu, Fujiwara, Toshifumi, Setsu, Nokitaka, Endo, Makoto, Matsumoto, Yoshihiro, Imajima, Takashi, Shinohara, Yudai, Ito, Mamoru, Yamaga, Satoru, Tanoue, Kenro, Arimizu, Kohei, Ohmura, Hirofumi, Hanamura, Fumiyasu, Yamaguchi, Kyoko, Isobe, Taichi, Ariyama, Hiroshi, Nakashima, Yasuharu, Akashi, Koichi, Baba, Eishi

“…Doxorubicin is a first-line therapy for patients with unresectable advanced soft tissue sarcoma (STS). However, because of cardiotoxicities, it is not used for…”
Get full text